Shanghai Desterli Biotechnology

Shanghai Desterli Biotechnology is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative peptide therapeutics for metabolic diseases. The company's primary focus is on multi-target agonists that modulate the incretin system, specifically targeting the GLP-1, GIP, and glucagon receptors. Its lead program, DSL-201, is a long-acting triple agonist designed to treat obesity and type 2 diabetes with improved efficacy and safety profiles. Desterli utilizes a proprietary peptide engineering platform to optimize drug properties such as potency and duration of action. Based in Shanghai, the company is backed by prominent investors including Qiming Venture Partners and Sequoia China.